(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

C ongress just passed a sweeping bill that includes changes to Medicaid expected to cut millions of people with low incomes ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...

In the mid-nineties, a friend of mine told me that he lost 30 friends and acquaintances to HIV/AIDS in just one week. It was a miracle that he was still alive. Although cases have decreased ...

President John Dramani Mahama has called for a youth-led national conversation on HIV prevention as the country faces a concerning surge in new infections, particularly among young people.

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...

Worldwide, at least seven people have been "cured" of HIV—or at least have had long-term sustained remission. This means that ...